News
REVBW
0.0091
+9.64%
0.0008
Weekly Report: what happened at REVB last week (0406-0410)?
Weekly Report · 21h ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 6d ago
Revelation Biosciences announces formation of AKI advisory board
TipRanks · 04/06 13:18
Weekly Report: what happened at REVB last week (0330-0403)?
Weekly Report · 04/06 10:27
Revelation Gemini data show ‘broad effect,’ says Roth Capital
TipRanks · 03/30 19:56
Revelation Biosciences presents additional data from Prime Clinical Study
TipRanks · 03/30 13:21
Revelation Biosciences Presents Additional Data Analysis From PRIME Study At International Conference On AKI & CRRT 2026
Benzinga · 03/30 13:02
Revelation Biosciences says Gemini normalizes inflammation in PRIME study CKD patients
Reuters · 03/30 13:02
Weekly Report: what happened at REVB last week (0323-0327)?
Weekly Report · 03/30 10:27
Revelation Biosciences to host fireside chat at the 38th Annual Roth Conference
Reuters · 03/24 13:00
Weekly Report: what happened at REVB last week (0316-0320)?
Weekly Report · 03/23 10:24
Revelation Biosciences Shareholders Approve Warrant Share Issuance
TipRanks · 03/19 20:51
Revelation Biosciences held a special shareholder meeting
Reuters · 03/19 20:19
Revelation Biosciences to host fireside chat at Roth Conference
Reuters · 03/19 13:00
Weekly Report: what happened at REVB last week (0309-0313)?
Weekly Report · 03/16 10:23
Weekly Report: what happened at REVB last week (0302-0306)?
Weekly Report · 03/09 10:23
Weekly Report: what happened at REVB last week (0223-0227)?
Weekly Report · 03/02 10:22
Revelation Biosciences price target lowered to $16 from $20 at Roth Capital
TipRanks · 02/27 13:39
Revelation Biosciences reports FY results
Seeking Alpha · 02/27 12:02
Revelation Biosciences Q4 net loss widens
Reuters · 02/26 22:00
More
Webull provides a variety of real-time REVBW stock news. You can receive the latest news about Rvltn Bioscnc through multiple platforms. This information may help you make smarter investment decisions.
About REVBW
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).